Companies › IDEAYA Biosciences
10 active drug programs in 24 registered trials: 10 Phase 2, 10 Phase 1, 4 Phase 3; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 3 | Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma … | Jan 2027 |
| Darovasertib Protein Kinase C (PKC) inhibitor | PRKC | Phase 3 | Uveal Melanoma | Apr 2027 |
| IDE196 | – | Phase 2 | Metastatic Uveal Melanoma | Jan 2027 |
| IDE397 MAT2A inhibitor | MAT2A | Phase 1 | Solid Tumor; NSCLC Adenocarcinoma | Jan 2027 |
| IDE-161 PARG inhibitor | PARG | Phase 1 | Advanced or Metastatic Solid Tumors | May 2027 |
| IDE034 Bispecific antibody targeting B7-H3 and PTK7 | B7H3, PTK7 | Phase 1 | Esophageal Squamous Cell Carcinoma | Jul 2027 |
| IDE892 PRMT5 inhibitor | PRMT5 | Phase 1 | NSCLC Adenocarcinoma | Apr 2028 |
| IDE161 | – | Phase 1 | Small-cell Lung Cancer | Jul 2029 |
| IDE849 DLL3-targeted bispecific antibody | DLL3 | Phase 1 | Small-cell Lung Cancer | Jul 2029 |
| IDE574 KAT6/KAT7 co-inhibitor | KAT6, KAT7 | Phase 1 | Cancer | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06357975 | Crizotinib | Phase 2 | Advanced Lymphoma | Oncology | Dec 2026 |
| NCT06360575 | Crizotinib | Phase 2 | Advanced Lymphoma | Oncology | Dec 2026 |
| NCT04794699 | IDE397 | Phase 1 | Solid Tumor | Oncology | Jan 2027 |
| NCT05987332 | Crizotinib | Phase 2 | Metastatic Uveal Melanoma | Oncology | Jan 2027 |
| NCT05987332 | IDE196 | Phase 2 | Metastatic Uveal Melanoma | Oncology | Jan 2027 |
| NCT03947385 | IDE196 | Phase 1 | Metastatic Uveal Melanoma | Oncology | Jan 2027 |
| NCT04439253 | Crizotinib | Phase 2 | Advanced Lymphoma | Oncology | Mar 2027 |
| NCT04439266 | Crizotinib | Phase 2 | Advanced Lymphoma | Oncology | Mar 2027 |
| NCT05907954 | Darovasertib | Phase 2 | Uveal Melanoma | Oncology | Apr 2027 |
| NCT05787587 | IDE-161 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | May 2027 |
| NCT07503808 | IDE034 | Phase 1 | Esophageal Squamous Cell Carcinoma | Oncology | Jul 2027 |
| NCT05014464 | Crizotinib | Phase 2 | Non-small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT06563999 | Crizotinib | Phase 2 | Lung Cancer Stage III | Oncology | Nov 2027 |
| NCT04693468 | Crizotinib | Phase 1 | Advanced Malignant Solid Neoplasm | Oncology | Dec 2027 |
| NCT07277413 | IDE397 | Phase 1 | NSCLC Adenocarcinoma | Oncology | Apr 2028 |
| NCT07277413 | IDE892 | Phase 1 | NSCLC Adenocarcinoma | Oncology | Apr 2028 |
| NCT07174583 | IDE849 | Phase 1 | Small-cell Lung Cancer | Oncology | Jul 2029 |
| NCT07174583 | IDE161 | Phase 1 | Small-cell Lung Cancer | Oncology | Jul 2029 |
| NCT07540572 | IDE574 | Phase 1 | Cancer | Oncology | Dec 2029 |
| NCT07015190 | Darovasertib | Phase 3 | Uveal Melanoma | Oncology | Oct 2030 |
| NCT07804186 | Darovasertib | Phase 3 | Uveal Melanoma | Oncology | Mar 2034 |
| NCT07804186 | Crizotinib | Phase 3 | Uveal Melanoma | Oncology | Mar 2034 |
| NCT02201992 | Crizotinib | Phase 3 | ALK Gene Rearrangement | Oncology | May 2036 |
| NCT05725200 | Crizotinib | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2038 |
Cash and short-term investments of $839m on 2026-09-30; operating cash outflow about $345m a year; runway about 29 months at that burn, to Mar 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
ArriVent BioPharma Servier Bio-Innovation Revolution Medicines MediLink Therapeutics (Suzhou) Cogent Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.